文献速递淋巴瘤

FCR方案一线治疗43例慢性淋巴细胞白血病的临床分析

[Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

该回顾性研究分析了43例初治慢性淋巴细胞白血病患者接受FCR方案(氟达拉滨+环磷酰胺+利妥昔单抗)的疗效与生存。结果显示总体反应率88.4%,完全缓解率46.5%,中位无进展生存67个月,5年总生存率70.5%。P53缺失和疗程数<4为不良预后因素。

要点

  • FCR方案一线治疗初治CLL的ORR为88.4%,CR率46.5%。
  • 中位PFS 67个月,5年OS率70.5%,10年OS率51.3%。
  • P53缺失和疗程数<4是PFS的不良预后因素。

核心结论

  • FCR方案一线治疗初治CLL反应率高、远期生存较理想,不良反应可接受,是适合患者的 important 治疗选择。

研究设计与样本

  • 回顾性分析2004年5月至2017年12月一线应用FCR方案治疗的43例CLL患者临床资料。

主要发现

  • 43例患者中男31例、女12例,中位年龄58岁(范围36~72岁)。
  • ORR为88.4%(38/43),CR 20例(46.5%),PR 18例(41.9%),SD 4例(9.3%),PD 1例(2.3%)。
  • 7例(16.3%)获得MRD阴性。
  • 中位随访51个月(范围6~167个月),中位PFS 67个月(范围29~105个月),中位OS未达到。
  • 5年PFS率(62.1±8.6)%,10年PFS率(31.0±14.3)%,5年OS率(70.5±8.3)%,10年OS率(51.3±13.8)%。

关键数值与推荐

  • IGHV未突变62.1%(18/29),P53缺失14.0%(6/43),RB1缺失18.6%(8/43),12号染色体三体25.6%(11/33),ATM缺失16.7%(7/42)。
  • 疗程数<4为影响OS的不良预后因素(P<0.05)。
  • P53缺失和疗程数<4为影响PFS的不良预后因素(P<0.001),多因素分析仍有意义[P53缺失:HR=7.65(95%CI 1.74~33.60),P=0.007;疗程数<4:HR=3.75(95%CI 1.19~11.80),P=0.025]。
  • 18例(41.9%)发生2~3级感染,19例(44.2%)发生3~4级血液学不良反应,1例(2.3%)发生肿瘤溶解综合征。

临床怎么用

  • 对适合的初治CLL患者,FCR方案可作为重要治疗选择,但需关注P53缺失及疗程数不足对预后的不良影响。

局限性

  • 回顾性分析,样本量43例,非随机对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the efficacy of fludarabine and cyclophosphamide combined with rituximab (FCR) in previously untreated patients with chronic lymphocytic leukemia (CLL) . Methods: The clinical data of 43 enrolled patients from May 2004 to December 2017 were analyzed the efficacy and survival results. Results: A total of 43 patients with 31 males and 12 females, and the median age was 58 years old (range 36 to72) before treatment. There were 8 patients with symptom B. The median number of peripheral blood lymphocyte was 26 (3-550) ×10(9)/L. IGHV unmutated was detected in 62.1% (18/29) patients, P53 deletion in 14% (6/43) patients, RB1 deletion in 18.6% (8/43) patients, Trisomy 12 in 25.6% (11/33) patients, ATM deletion in 16.7% (7/42) patients, respectively. The median number of treatment courses administered was 4 (range 2-6) . Twenty patients obtained CR (46.5%) , 18 patients obtained PR, 4 patients were SD, 1 patient was PD. The overall response rate (ORR) was 88.37%. Seven patients obtained MRD negative. After the median follow-up time of 51 (6-167) months, median PFS was 67 (29-105) months, median OS was not reach, 5-year PFS was (62.1±8.6) %, 10-year PFS was (31±14.3) %, 5-year OS was (70.5±8.3) %, and 10-year OS was (51.3±13.8) %. Less than 4 courses predicted adverse OS (P<0.05) . P53 deletion and less than 4 courses were associated with poor PFS (P<0.001) , and the prognostic value still remained after multivariate analysis[HR=7.65 (95%CI 1.74-33.60) , P=0.007; HR=3.75 (95%CI 1.19-11.80) , P=0.025]. Eighteen patients (41.9%) appeared grade 2-3 infection after chemotherapy, and 19 patients (44.2%) appeared grade 3-4 hematological adverse reactions. One patient (2.3%) was developed tumor lysis syndrome. All adverse reactions were controlled or recovered spontaneously. Conclusion: Previously untreated CLL patients treated with FCR had a high response rate and good survival rate, which is an important treatment choice for fit patients. 目的: 探讨FCR方案(氟达拉滨+环磷酰胺+利妥昔单抗)一线治疗慢性淋巴细胞白血病(CLL)的疗效。 方法: 回顾性分析2004年5月至2017年12月一线应用FCR方案治疗的43例CLL患者的临床资料。 结果: ①43例CLL患者中,男31例,女12例,接受FCR方案治疗时中位年龄58(36~72)岁;8例患者伴B症状,外周血中位淋巴细胞计数26(3~550)×10(9)/L,IGHV基因未突变62.1%(18/29),P53基因缺失14.0%(6/43),RB1基因缺失18.6%(8/43),12号染色体三体占25.6%(11/33),ATM基因缺失16.7%(7/42)。全部患者FCR方案中位疗程数为4(2~6)个。②全部43例患者的总体反应率(ORR)为88.4%(38/43),完全缓解(CR)20例(46.5%),部分缓解(PR)18例(41.9%),疾病稳定(SD)4例(9.3%),疾病进展(PD)1例(2.3%);7例(16.3%)患者获得微小残留病(MRD)阴性。③中位随访51(6~167)个月,中位无进展生存(PFS)时间为67(29~105)个月,中位总生存(OS)时间未达到,5年PFS率为(62.1±8.6)%,10年PFS率为(31.0±14.3)%,5年OS率为(70.5±8.3)%,10年OS率为(51.3±13.8)%。疗程数<4为影响OS的不良预后因素,P53基因缺失、疗程数<4为影响PFS的不良预后因素(P<0.001),且在多因素分析中仍具有预后意义[P53基因缺失:HR=7.65(95%CI 1.74~33.60),P=0.007;疗程数<4:HR=3.75(95%CI 1.19~11.80),P=0.025]。④18例(41.9%)患者于化疗后发生2~3级感染,19例(44.2%)发生3~4级血液学不良反应,1例(2.3%)患者发生肿瘤溶解综合征,所有不良反应经对症处理均恢复。 结论: FCR方案一线治疗CLL的治疗反应及远期生存较理想,不良反应可接受。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang TY, Yi SH, Wang Y, et al. [Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34455740. doi:10.3760/cma.j.issn.0253-2727.2021.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。